详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Zhou, Caicun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Wang, Ziping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Sun, Meili[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Cao, Lejie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Ma, Zhiyong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Wu, Rong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Yu, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Yao, Wenxiu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17]

机构： [1]Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China [2]Peking University Cancer Hospital and Institute, Beijing, China [3]Central Hospital Affiliated to Shandong First Medical University, Jinan, China [4]Department of Respiratory and Critical Care Medicine, Anhui Provincial Hospital, Hefei, China [5]The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [6]Department of Oncology, Shengjing Hospital of China Medical University, Shengyang, China [7]Harbin Medical University Cancer Hospital, Harbin, China [8]Sichuan Cancer Hospital & Institute, Chengdu, China [9]Fudan University Shanghai Cancer Center, Shanghai, China [10]Hunan Cancer Hospital, Changsha, China [11]Fujian Provincial Cancer Hospital, Fuzhou, China [12]The First Hospital of Jilin University, Changchun, China [13]The Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [14]Department of Thoracic Oncology, Cancer Centre, Sichuan University West China Hospital, Chengdu, China [15]The Second Xiangya Hospital of Central South University, Changsha, China [16]CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China [17]CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

出处：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China [2]Peking University Cancer Hospital and Institute, Beijing, China [3]Central Hospital Affiliated to Shandong First Medical University, Jinan, China [4]Department of Respiratory and Critical Care Medicine, Anhui Provincial Hospital, Hefei, China [5]The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [6]Department of Oncology, Shengjing Hospital of China Medical University, Shengyang, China [7]Harbin Medical University Cancer Hospital, Harbin, China [8]Sichuan Cancer Hospital & Institute, Chengdu, China [9]Fudan University Shanghai Cancer Center, Shanghai, China [10]Hunan Cancer Hospital, Changsha, China [11]Fujian Provincial Cancer Hospital, Fuzhou, China [12]The First Hospital of Jilin University, Changchun, China [13]The Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [14]Department of Thoracic Oncology, Cancer Centre, Sichuan University West China Hospital, Chengdu, China [15]The Second Xiangya Hospital of Central South University, Changsha, China [16]CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China [17]CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC)

文献详情